📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 18:46
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
22 announcements match the current filters (relevance ≥ 5).
Panacea Biotec Q1 FY27: Revenue Grows 19.7% YoY to ₹199.57 Cr; Net Profit Declines to ₹2.20 Cr
Panacea Biotec reported a consolidated revenue of ₹199.57 Cr for Q1 FY27, a 19.7% increase from ₹166.70 Cr in the same quarter last year. Despite the top-line growth, consolidated net profit fell by 44.4% to ₹2.20 Cr compared to ₹3.96 Cr in Q1 FY26. The company recorded an exceptional gain of ₹2.74 Cr during the quarter, which supported the bottom line. The 42nd Annual General Meeting (AGM) is scheduled for September 29, 2026.
Confidence: HIGH
What changedThe company has transitioned from a net loss in the preceding quarter (Q4 FY26) to a marginal profit in Q1 FY27, though profit is lower on a year-on-year basis.
Why it mattersWhile revenue growth is healthy, the company's thin margins and reliance on exceptional items for profitability remain concerns for a firm with a high debt-to-equity ratio of 0.93.
Consolidated Revenue (Q1 FY27): ₹199.57 CrRevenue vs TTM Revenue: 31.2%Consolidated Net Profit: ₹2.20 CrYoY Revenue Growth: 19.7%Exceptional Gain: ₹2.74 CrAGM Date: September 29, 2026
📅 Short termThe market may react neutrally to the results as the strong revenue growth is offset by a decline in year-on-year profitability.
📈 Long termLong-term sustainability depends on the company's ability to resolve liquidity constraints and successfully scale its vaccine and transplantation segments to improve ROCE from its current negative levels.
⚠ Risk flags
- High debt-to-equity ratio (0.93)
- History of debt servicing delays (CARE D rating)
- Thin net profit margins
- Dependence on exceptional items for bottom-line support
Key Highlights
Consolidated revenue from operations rose to ₹199.57 Cr from ₹166.70 Cr in the year-ago period.
Consolidated net profit after tax stood at ₹2.20 Cr, down from ₹3.96 Cr in Q1 FY26.
Total consolidated expenses increased by 14.6% YoY to ₹202.98 Cr, driven by higher raw material costs.
Exceptional items contributed ₹2.74 Cr to the consolidated profit before tax of ₹3.57 Cr.
The company announced a book closure period from September 25 to September 29, 2026, for the upcoming AGM.
👀 What to Watch
Investors should monitor the company's operating margins and its ability to manage high debt (₹265 Cr) given the historical CARE D rating. The execution of the planned 10-12 new product launches in the domestic market will be a key driver for future profitability.
Rs 78.24 Cr order from UNICEF for bOPV supply in CY2028
Panacea Biotec has secured a Letter of Award from UNICEF for the supply of bivalent Oral Polio Vaccine (bOPV) worth approximately $8.205 million (Rs 78.24 crore). This order is scheduled for execution during the calendar year 2028 and falls under an existing Long-Term Agreement (LTA) valid until March 2030. The order value represents roughly 12.2% of the company's TTM revenue of Rs 640 crore, providing long-term revenue visibility. However, the company continues to operate under financial stress with a CARE D rating and negative ROCE.
Confidence: HIGH
What changedThe company has received a specific order allocation for CY2028 under its previously announced multi-year agreement with UNICEF.
Why it mattersThis award reinforces Panacea's position in the global vaccine market and provides a guaranteed revenue stream for 2028, which is vital given the company's current negative profitability.
Order Value: Rs 78.24 CrOrder vs TTM Revenue: 12.2%Execution Year: CY2028TTM Revenue: Rs 640 CrLTA Validity: March 31, 2030
📅 Short termThe news is likely to be viewed positively by the market as it confirms continued order flow from a major international agency like UNICEF.
📈 Long termThe order provides structural revenue visibility for the vaccine segment through 2028, though long-term sustainability depends on improving the balance sheet.
⚠ Risk flags
- Execution risk due to existing debt servicing delays (CARE D rating)
- Long lead time until execution (2028)
- Liquidity constraints potentially impacting R&D and capacity
Key Highlights
Order value of approximately US$ 8.205 million (~Rs 78.24 crore) for bOPV supply.
Execution timeline specifically designated for the Calendar Year 2028.
Part of a broader Long-Term Agreement (LTA) spanning from April 1, 2026, to March 31, 2030.
Order covers vaccine supply in both 10 and 20 dose presentations.
Order value is significant at ~12.2% of the TTM revenue of Rs 640 crore.
👀 What to Watch
Investors should monitor the company's progress in resolving its liquidity constraints and debt servicing issues (CARE D rating), as these are critical for fulfilling long-term supply commitments.
Panacea Biotec Joins €11.1M EU-Funded DENSTAR Project for DengiAll® Vaccine Licensure
Panacea Biotec has launched the DENSTAR project, a four-year initiative funded by an €11.1 million grant from the Global Health EDCTP3 JU, supported by the European Union. The project aims to advance the licensure of Panacea's tetravalent dengue vaccine, DengiAll®, in sub-Saharan Africa and facilitate its broader global use. As a key partner in a 10-member international consortium, Panacea will participate in Phase I/III studies to confirm vaccine safety and efficacy in African populations. The vaccine is designed as a single-dose, cost-efficient solution that does not require prior serological testing, positioning it for large-scale deployment in low- and middle-income countries.
Key Highlights
Launch of the 48-month DENSTAR project starting June 1, 2026, to advance DengiAll® vaccine licensure.
Project funded by a €11,091,138.75 grant from the Global Health EDCTP3 JU, supported by the European Union.
Consortium includes 10 partners from 9 countries, including the University of Siena and Johns Hopkins University.
DengiAll® is a single-dose tetravalent vaccine currently in late-stage development in India.
The project will conduct Phase I/III studies in Africa and evaluate efficacy against DENV-4 using Controlled Human Infection Models.
👀 What to Watch
Investors should monitor the progress of clinical trials in Africa and the regulatory timeline for DengiAll® in India, as successful licensure could open significant global markets. The external funding reduces the financial burden of R&D for this specific project.
Panacea Biotec FY26: Consolidated Revenue up 14%, Net Loss narrows to ₹7.16 Cr
Panacea Biotec reported a 14% increase in consolidated total income to ₹656.67 crore for FY26, while the consolidated net loss narrowed slightly to ₹7.16 crore from ₹8.72 crore in FY25. However, standalone performance was weaker, with the net loss widening significantly to ₹29.88 crore from ₹15.23 crore in the previous year. Due to persistent losses, the company has skipped dividend payments for the fiscal year and appointed Mr. Rajinder Singh Manku as an Independent Director.
Key Highlights
Consolidated total income rose 13.3% YoY to ₹65,667 Lakh in FY26.
Consolidated net loss narrowed to ₹716 Lakh from ₹872 Lakh in FY25.
Standalone net loss widened to ₹2,988 Lakh compared to ₹1,523 Lakh in the previous year despite revenue growth.
The Board decided to pass over dividends for FY26 on account of losses.
Mr. Rajinder Singh Manku appointed as Independent Director for a 5-year term effective July 1, 2026.
👀 What to Watch
Investors should exercise caution as the company continues to report losses at both standalone and consolidated levels. Monitor if the double-digit revenue growth can eventually lead to a turnaround in bottom-line profitability.
Panacea Biotec FY26 Consolidated Loss Narrows to ₹7.16 Cr; Revenue Up 13% to ₹640 Cr
Panacea Biotec Limited reported a consolidated total income of ₹65,667 lakh for the financial year ended March 31, 2026, marking a 13.3% growth compared to ₹57,975 lakh in FY25. The consolidated net loss narrowed to ₹716 lakh from ₹872 lakh in the previous year, aided by exceptional items of ₹1,950 lakh. However, standalone performance remained under pressure with the net loss widening significantly to ₹2,988 lakh from ₹1,523 lakh. Consequently, the company has skipped dividend payments for the year.
Key Highlights
Consolidated revenue from operations increased by 14.4% YoY to ₹63,977 lakh in FY26.
Consolidated net loss for the year narrowed to ₹716 lakh compared to a loss of ₹872 lakh in FY25.
Standalone net loss widened by 96% to ₹2,988 lakh for FY26, up from ₹1,523 lakh in the previous year.
The Board of Directors recommended passing over dividends for both equity and preference shares due to losses.
Mr. Rajinder Singh Manku was appointed as an Additional Independent Director for a 5-year term starting July 1, 2026.
👀 What to Watch
Investors should exercise caution as the widening standalone losses and lack of dividends reflect ongoing operational challenges despite the marginal improvement in consolidated bottom-line figures.
Panacea Biotec Reports Fire at Baddi Oncology Facility; Operations Disrupted for 5-7 Days
Panacea Biotec's subsidiary, Panacea Biotec Pharma Limited, reported a fire incident at its Oncology Quality Control Laboratory in Baddi on April 30, 2026. The fire, caused by a short circuit, was quickly controlled, but operations at the facility are expected to be disrupted for approximately 5 to 7 days. Management has confirmed there were no casualties and that the facility is adequately insured. Importantly, the company does not anticipate a material impact on its overall financial performance due to this temporary halt.
Key Highlights
Fire incident occurred at the Baddi, Himachal Pradesh facility on April 30, 2026, due to a short circuit.
Operations at the Oncology Facility are temporarily disrupted for an estimated period of 5 to 7 days.
Zero human casualties or injuries were reported during the incident.
Management states the disruption is not likely to have a material impact on the company's financials.
The facility has adequate insurance coverage and the insurance company has been notified.
👀 What to Watch
Investors should monitor for a follow-up announcement confirming the resumption of operations within the 7-day window. As the financial impact is expected to be immaterial, no immediate change in investment strategy is required.
Panacea Biotec Wins Tax Appeal; ITAT Cancels ₹9.16 Crore Demand
Panacea Biotec has received a favorable ruling from the Income Tax Appellate Tribunal (ITAT) regarding Assessment Year 2020-21. The ITAT set aside a previous order that had raised a tax demand of ₹9.16 Crore. This demand was originally based on a ₹3.44 Crore disallowance of expenses under Section 14A of the Income Tax Act. The ruling effectively cancels the entire demand, providing a positive financial impact for the company by removing this liability.
Key Highlights
ITAT set aside the CIT(A) order dated August 14, 2025, for Assessment Year 2020-21
Cancellation of a tax demand amounting to ₹9.16 Crore
Deletion of expense disallowance of ₹3.44 Crore previously added under Section 14A
The ruling follows a Rectified Assessment Order originally passed on October 10, 2023
👀 What to Watch
This is a positive development as it removes a contingent liability and improves the company's financial position. Investors should continue to monitor the company's core business performance alongside such legal resolutions.
Panacea Biotec Secures INR 20.79 Crore Vaccine Supply Order from CMSS
Panacea Biotec Limited has received a Letter of Award from the Central Medical Services Society (CMSS), under the Ministry of Health and Family Welfare, for the supply of Diphtheria and Tetanus (Td) vaccines. The total value of the contract is INR 20.79 Crore. The supply is scheduled to be executed in multiple tranches starting from September/October 2026 and concluding by November/December 2028. This domestic order provides long-term revenue visibility for the company's vaccine segment.
Key Highlights
Total contract value aggregates to INR 20.79 Crore for Td Vaccine supply
Order awarded by Central Medical Services Society (CMSS), a domestic government entity
Execution timeline spans approximately two years from late 2026 to late 2028
The contract involves Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP
👀 What to Watch
Investors should note this as a positive development for revenue stability, though the execution starts in late 2026. Monitor the company's ability to secure similar high-volume government contracts to improve its order book.
Panacea Biotec Receives ₹22.88 Cr GST Demand; High Court Issues Interim Stay
Panacea Biotec has received a demand order for ₹22.88 crore from the CGST authorities, which includes a principal tax amount of ₹11.44 crore and an equivalent penalty. The dispute pertains to the alleged non-payment of GST on corporate guarantees totaling ₹864 crore issued between April 2019 and March 2022. Crucially, the company has already obtained an interim stay from the Punjab & Haryana High Court, protecting it from coercive recovery actions. The management maintains that the demand is not legally maintainable and is taking steps to contest the order.
Key Highlights
Total demand of ₹22.88 crore comprising ₹11.44 crore GST and ₹11.44 crore penalty.
Dispute relates to corporate guarantees worth ₹864 crore provided over a period of 1,074 days.
Interim stay order granted by Punjab & Haryana High Court prevents coercive action by authorities.
Company filed its response to the Show Cause Notice on March 27, 2026, and considers the demand non-maintainable.
👀 What to Watch
Investors should monitor the final outcome of the writ petition in the High Court as it will determine if the ₹22.88 crore liability materializes. While the stay order mitigates immediate cash flow risks, the legal uncertainty remains a factor for the company's valuation.
Panacea Biotec Faces ₹9.38 Cr Tax Penalty Demand as CIT(A) Dismisses Appeals
Panacea Biotec Limited has received an adverse ruling from the Commissioner of Income Tax (Appeals), New Delhi, which dismissed the company's appeals against penalty orders. These orders pertain to alleged under-reporting of income for the Assessment Years 2017-18, 2020-21, and 2021-22. The aggregate demand resulting from these penalties stands at approximately ₹9.38 crore. While the company intends to challenge this order before a higher appellate authority, the dismissal of the current appeal reinforces the immediate tax liability risk.
Key Highlights
CIT(A) dismissed three appeals against penalty orders issued by the Assistant Commissioner of Income Tax.
The total aggregate tax demand involved in the litigation is approximately ₹9.38 crore.
The penalties relate to alleged under-reporting of income for AY 2017-18, 2020-21, and 2021-22.
Panacea Biotec plans to file a further appeal with the next appellate authority to contest the demand.
Management currently maintains that the demand will not have a relevant impact on operations or financial activities.
👀 What to Watch
Investors should monitor the progress of the next appeal as a final unfavorable outcome would necessitate a ₹9.38 crore cash outflow. The news is likely to weigh slightly on the stock price in the short term due to the legal setback.
Panacea Biotec Wins Major Tax Case; ₹329.49 Crore Tax Demand Cancelled by ITAT
Panacea Biotec has received a favorable ruling from the Income Tax Appellate Tribunal (ITAT) regarding long-standing tax disputes for Assessment Years 2005-06 to 2012-13. The ITAT dismissed eight appeals by the tax department and allowed two appeals by the company, effectively quashing the previous assessment orders. This decision results in the cancellation of a massive tax demand totaling ₹329.49 Crore. The ruling removes a significant contingent liability and potential penalty exposure from the company's financial records.
Key Highlights
ITAT quashed assessment orders for eight Assessment Years spanning 2005-06 to 2012-13.
Cancellation of a total tax demand amounting to ₹329.49 Crore previously raised by the Assessing Officer.
Deletion of all expense disallowances that were under litigation since Financial Year 2015-16.
The ruling dismisses eight appeals filed by the Deputy Commissioner of Income Tax (DCIT) against the company.
👀 What to Watch
This is a significant positive development that strengthens the balance sheet by removing a large liability; investors should monitor if the tax department files a further appeal in the High Court.
Panacea Biotec Receives ₹45.71 Crore Income Tax Demand for AY 2015-16
Panacea Biotec has received a demand order of ₹45.71 crore from the Income Tax Department for the Assessment Year 2015-16. The demand stems from the disallowance of certain expenditures under Section 37 of the IT Act, which the authorities allege violated Medical Council of India (MCI) regulations. The company contends that the demand is misplaced as it has sufficient brought-forward losses to offset any taxable income. Management is currently pursuing legal remedies, including filing a rectification application and an appeal before the relevant authorities.
Key Highlights
Total tax demand of ₹45.71 crore including interest for Assessment Year 2015-16.
Demand issued by the Deputy Commissioner of Income Tax, Central Circle 29, Delhi.
Disallowances based on alleged violations of Medical Council of India (MCI) Regulations.
Company claims no actual tax liability due to availability of brought-forward losses.
Legal recourse initiated via rectification application and appellate authority appeal.
👀 What to Watch
Investors should monitor the progress of the appeal and rectification process, as any final unfavorable ruling could impact the company's financial position despite the current claim of tax losses.
Panacea Biotec Q3 Results: Consolidated Net Profit at ₹389 Lakh; Standalone Loss Widens
Panacea Biotec reported a consolidated net profit of ₹389 lakh for the quarter ended December 31, 2025, a slight decline from ₹444 lakh in the previous year. Consolidated revenue from operations grew marginally to ₹16,519 lakh compared to ₹16,349 lakh YoY. However, the standalone business faced significant pressure, reporting a net loss of ₹736 lakh against a profit of ₹965 lakh in the same period last year. The company continues to benefit from exceptional income, including a ₹858 lakh settlement with Apotex Inc. and deferred consideration from previous brand sales.
Key Highlights
Consolidated revenue from operations increased 1.04% YoY to ₹16,519 lakh.
Formulations segment EBIT turned positive at ₹906 lakh compared to a loss of ₹758 lakh in Q3 FY25.
Vaccines segment reported a loss of ₹257 lakh at the EBIT level for the quarter.
Exceptional income of ₹1,679 lakh recognized in 9M FY26, including ₹858 lakh from a settlement with Apotex Inc.
Standalone net loss for 9M FY26 widened significantly to ₹2,970 lakh from ₹284 lakh in 9M FY25.
👀 What to Watch
Investors should exercise caution as the company remains loss-making on a 9-month consolidated basis despite the quarterly profit. Monitor the vaccines segment's recovery and the company's ability to generate consistent operational cash flow without relying on exceptional items.
Panacea Biotec Q3 FY26 Results: Consolidated Net Profit at ₹3.89 Cr; Revenue Grows 1% YoY
Panacea Biotec reported a consolidated net profit of ₹3.89 crore for Q3 FY26, a slight decline from ₹4.44 crore in the same quarter last year. Consolidated revenue from operations grew marginally by 1% YoY to ₹165.19 crore. For the nine-month period, the company remains in a net loss of ₹6.16 crore, though this narrowed from a loss of ₹6.73 crore in the previous year. The results were significantly supported by an exceptional income of ₹16.79 crore in the 9M period, including a settlement with Apotex Inc.
Key Highlights
Consolidated Q3 revenue reached ₹165.19 crore, a marginal 1% increase over the previous year's ₹163.49 crore.
Formulations segment profit improved significantly to ₹9.06 crore from a loss of ₹7.58 crore in Q3 FY25.
Vaccines segment reported a loss of ₹2.57 crore for the quarter despite revenue of ₹99.24 crore.
Exceptional income of ₹16.79 crore for 9M FY26 includes ₹8.58 crore from a settlement with Apotex Inc.
Standalone net loss stood at ₹7.36 crore for Q3 FY26, compared to a profit of ₹9.65 crore in Q3 FY25.
👀 What to Watch
Investors should monitor the company's ability to sustain operational profitability without relying on exceptional items and brand sale deferrals. While the turnaround in the formulations segment is positive, the core vaccine business remains under pressure.
Panacea Biotec's Baddi Facility Receives GMP Non-Compliance From Hungary Regulator
Panacea Biotec's subsidiary facility in Baddi has received a 'Statement of non-compliance' with Good Manufacturing Practices (GMP) from Hungary's NCPHP, resulting in the revocation of its GMP certificates. The regulator has proposed halting supplies of non-vital products to the EU market, though no quality risks were found in products already released. The financial impact is expected to be minimal as the EU market contributed only 0.32% of the company's total consolidated net revenues in FY 2024-25. The company is currently implementing corrective and preventive actions (CAPA) to seek a re-inspection and restore compliance.
Key Highlights
NCPHP Hungary issued a Statement of non-compliance with GMP for the Baddi facility on February 03, 2026.
All valid GMP certificates issued by NCPHP for the facility have been revoked following the inspection.
Revenue from the European Union market accounted for only 0.32% of consolidated net revenues in FY 2024-25.
No quality risks were observed by regulators for products already released into the market.
Company is implementing CAPA and will request a re-inspection at the earliest to restore certificates.
👀 What to Watch
Investors should note that while the immediate revenue impact is negligible at 0.32%, the regulatory failure at a major facility is a sentiment negative. Monitor the timeline for CAPA implementation and successful re-inspection to ensure no broader compliance issues exist.
Panacea Biotec Completes Phase III Enrollment for DengiAll Vaccine with 10,335 Participants
Panacea Biotec has achieved a major milestone by completing the enrollment of 10,335 participants for the Phase III clinical trials of DengiAll, India's first indigenous single-shot dengue vaccine. The trial, conducted in collaboration with ICMR, will now move into a two-year monitoring phase to evaluate the vaccine's efficacy and immunogenicity. This development keeps the company on track for a projected market entry by 2027. Successful commercialization would address a significant unmet medical need in tropical regions, potentially creating a substantial long-term revenue stream.
Key Highlights
Completed enrollment of 10,335 study participants for Phase III clinical trials of DengiAll vaccine.
DengiAll is positioned as India's first indigenous single-shot tetravalent dengue vaccine candidate.
Two-year monitoring period initiated to examine long-term efficacy and immunogenicity post-administration.
Commercial market launch is anticipated by 2027 following the completion of the observation period.
Project is being executed in collaboration with the Indian Council of Medical Research (ICMR).
👀 What to Watch
Investors should maintain a positive outlook on the company's R&D pipeline as this milestone reduces execution risk. However, since commercialization is expected only by 2027, this remains a long-term play with interim clinical data being the next key catalyst.
Panacea Biotec Receives ₹9.38 Crore Income Tax Penalty Demand
Panacea Biotec Limited has received three demand orders from the Income Tax Department totaling ₹9.38 Crore. The penalties are attributed to alleged under-reporting of income for Assessment Years 2017-18, 2020-21, and 2021-22. The company has declared the demand as not maintainable and intends to file an appeal with the appellate authority. While the company does not foresee an immediate operational impact, the final resolution of this litigation will determine the actual financial outflow.
Key Highlights
Aggregate penalty demand of ₹9.38 Crore received from the Assistant Commissioner of Income Tax, Delhi.
Specific demands include ₹5.55 Crore for AY 2017-18, ₹3.11 Crore for AY 2020-21, and ₹0.72 Crore for AY 2021-22.
Penalties imposed under Section 270A of the Income Tax Act, 1961 for alleged under-reporting of income.
Company plans to contest the orders by filing an appeal with the relevant appellate authority.
👀 What to Watch
Monitor the progress of the tax appeal as a negative outcome would result in a cash outflow of ₹9.38 Crore. No immediate action is required as the company is actively contesting the demand.
Panacea Biotec Secures ₹80 Crore Additional Vaccine Supply Orders from UNICEF
Panacea Biotec has received an amendment to its existing contract with UNICEF for the supply of its WHO pre-qualified Pentavalent vaccine, Easyfive-TT®. The total value of the award has been increased by approximately $8.93 million (around ₹80 Crore) for the years 2026 and 2027. Specifically, the 2026 allocation increased by $2.55 million, while the 2027 allocation saw a combined increase and additional award totaling $6.38 million. This development strengthens the company's long-term revenue visibility and reinforces its partnership with international health organizations.
Key Highlights
Total contract value increased by $8.93 million (~₹80 Crore) for CY2026 and CY2027
2026 supply value increased by $2.55 million to a total of $16.8 million
2027 supply value increased by $6.38 million through amendments and additional awards
Supplies involve the WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT®
The contract is with an international entity (UNICEF), ensuring high credit quality
👀 What to Watch
This order provides strong revenue visibility for the next two years and validates the company's standing in the global vaccine market. Investors should monitor the impact on margins and the company's ability to scale production to meet these increased requirements.
Panacea Biotec: CFO Appointment, Company Secretary Change & Policy Revision
Panacea Biotec has announced key management changes. Mr. Vinod Goel, currently Group CFO, is appointed as CFO effective December 16, 2025, succeeding Mr. Devender Gupta. Consequently, Mr. Goel will cease to be the Company Secretary. Mr. Ankit Jain is appointed as Company Secretary and Compliance Officer from December 16, 2025. The board also adopted a revised policy for determining the Materiality of Events.
Key Highlights
Mr. Vinod Goel appointed as Group Chief Financial Officer and Head Legal & Corporate Governance w.e.f. December 16, 2025.
Mr. Ankit Jain appointed as General Manager – Legal & Company Secretary w.e.f. December 16, 2025.
Mr. Vinod Goel has over 35 years of post-qualification experience.
Mr. Ankit Jain has around 15 years of experience in corporate governance and regulatory compliance.
Revised Policy for determining Materiality of Events / Information effective December 16, 2025.
👀 What to Watch
Investors should note the changes in key management personnel. Monitor future filings for any impact from the revised policy on materiality of events.
Panacea Biotec appoints Ankit Jain as Company Secretary w.e.f. Dec 16, 2025
Panacea Biotec Limited announced the appointment of Mr. Ankit Jain as the Company Secretary & Compliance Officer, effective December 16, 2025. This follows the cessation of Mr. Vinod Goel from the role of Company Secretary and Compliance Officer on December 15, 2025, due to his appointment as Group CFO. Mr. Jain, aged about 38 years, previously served as Assistant General Manager - Legal of the company’s wholly owned subsidiary, Panacea Biotec Pharma Ltd. The board also revised the policy for determining materiality of events and authorized key managerial personnel for disclosures.
Key Highlights
Ankit Jain appointed as Company Secretary & Compliance Officer w.e.f. December 16, 2025
Vinod Goel appointed as Group CFO and Head Legal & Corporate Governance w.e.f. December 16, 2025
Vinod Goel ceases to be Company Secretary and Compliance Officer w.e.f. December 15, 2025
Ankit Jain has around 15 years of experience in corporate governance
Board meeting concluded at 03:36 P.M. on December 15, 2025
👀 What to Watch
Investors should monitor the company's filings and announcements for further updates on key managerial personnel changes and strategic direction. No immediate action is required.
